MapLight Therapeutics (MPLT) Cash & Equivalents (2024 - 2025)
MapLight Therapeutics (MPLT) reported Cash & Equivalents of $453.1 million for Q4 2025, up 1084.48% on a YoY basis from $38.3 million in Q4 2024, and up 606.36% sequentially from $64.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Cash & Equivalents (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Cash & Equivalents data on file, last reported at $453.1 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 1084.48% year-over-year to $453.1 million; the trailing twelve-month figure through Dec 2025 stood at $453.1 million (up 1084.48% YoY), and the FY2025 full-year result was $453.1 million, up 1084.48% from the prior year.
- Cash & Equivalents advanced to $453.1 million in Q4 2025, from $64.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $453.1 million in Q4 2025 to a low of $38.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 453.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 453.10 Mn |
| Sep 30, 2025 | 64.15 Mn |
| Dec 31, 2024 | 38.25 Mn |